These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3470166)

  • 41. Enoxacin decreases the clearance of theophylline in man.
    Wijnands WJ; Vree TB; Van Herwaarden CL
    Br J Clin Pharmacol; 1985 Dec; 20(6):583-8. PubMed ID: 3867394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of renal failure on the kinetics of zimeldine and norzimelidine.
    Ferry N; Cuisinaud G; Cochat P; Pozet N; Zech PY; Sassard J
    Eur J Clin Pharmacol; 1985; 28(4):453-6. PubMed ID: 3161742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of renal function on enalapril kinetics.
    Lowenthal DT; Irvin JD; Merrill D; Saris S; Ulm E; Goldstein S; Hichens M; Klein L; Till A; Harris K
    Clin Pharmacol Ther; 1985 Dec; 38(6):661-6. PubMed ID: 2998676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enoxacin pharmacokinetics and efficacy in CF-1 mice.
    Chartrand SA; Scribner RK; Marks MI; Dice J
    J Antimicrob Chemother; 1987 Feb; 19(2):221-4. PubMed ID: 3553134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of piperacillin dose on elimination kinetics in renal impairment.
    Aronoff GR; Sloan RS; Brier ME; Luft FC
    Eur J Clin Pharmacol; 1983; 24(4):543-7. PubMed ID: 6222908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assay of enoxacin in human serum and prostatic tissue by HPLC.
    White LO; Bowyer HM; McMullin CH; Desai K
    J Antimicrob Chemother; 1988 Apr; 21(4):512-3. PubMed ID: 3163995
    [No Abstract]   [Full Text] [Related]  

  • 47. Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers.
    Jaehde U; Sörgel F; Naber KG; Zürcher J; Schunack W
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2092-7. PubMed ID: 8540722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enoxacin concentration in human prostatic tissue after oral administration.
    Rannikko S; Malmborg AS
    J Antimicrob Chemother; 1986 Jan; 17(1):123. PubMed ID: 2419299
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical and pharmacokinetic studies on enoxacin in ear, nose and throat infections.
    Federspil PJ; Lind A; Tiesler E; Schmidt B
    Infection; 1986; 14 Suppl 3():S211-2. PubMed ID: 3463545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
    Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
    Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.
    Bailey RR; Walker RJ; Lynn KL; Donaldson IM; Peddie BA; Dobbs BR
    Br J Clin Pharmacol; 1988 Feb; 25(2):223-8. PubMed ID: 3162809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enoxacin absorption and elimination characteristics.
    Toothaker RD
    Clin Pharmacokinet; 1989; 16 Suppl 1():52-8. PubMed ID: 2653697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.
    Ferry N; Geoffroy J; Pozet N; Cuisinaud G; Benzoni D; Zech PY; Sassard J
    Br J Clin Pharmacol; 1988 Mar; 25(3):359-66. PubMed ID: 3358898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics, pharmacology of atenolol and effect of renal disease.
    Wan SH; Koda RT; Maronde RF
    Br J Clin Pharmacol; 1979 Jun; 7(6):569-74. PubMed ID: 465278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.
    Singlas E; Pioger JC; Taburet AM; Colin JN; Fillastre JP
    Clin Pharmacol Ther; 1989 Aug; 46(2):190-7. PubMed ID: 2758728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
    Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of renal impairment on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A; Gambertoglio JG
    Clin Pharmacokinet; 1997; 33 Suppl 1():32-8. PubMed ID: 9433654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo diffusion of enoxacin in healthy renal and adenomatous prostate tissue in man.
    Charton M; Timbal Y
    Eur Urol; 1990; 17(3):252-6. PubMed ID: 1693576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary enoxacin concentration and excretion after a single dose.
    Bailey RR; Dobbs BR; Gazeley LR
    N Z Med J; 1985 Mar; 98(774):159. PubMed ID: 3856178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.